BeiGene achieves first half-year profit
August 8, 2025
Source: drugdu
108
On August 6, BeiGene announced its second-quarter 2025 US stock results and key semi-annual financial data for its A-share listings. In the first half of 2025, BeiGene achieved total operating revenue of 17.518 billion yuan, a year-on-year increase of 46.0%. Product revenue reached 17.360 billion yuan, a year-on-year increase of 45.8%. Net profit attributable to the parent company was 450 million yuan, marking the company's first-half year return to profitability. These first-half results demonstrate significant breakthroughs in product sales and market expansion, which will significantly boost investor confidence, drive stock price appreciation, enhance the company's valuation and attractiveness in the capital markets, and lay a solid foundation for future financing and development.
https://finance.sina.com.cn/roll/2025-08-08/doc-infkfkhi3879307.shtml
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Breaking the Mold and Forging a New Path! From Insulin Technology Pioneer to Global Innovation Competitor December 4, 2025
- A subsidiary of Kingfriend Pharmaceutical Co., Ltd. has received FDA approval for its self-developed injectable dapavancin December 4, 2025
- Major ophthalmic new drug successfully completed Phase III trials December 4, 2025
- Simcere Pharmaceutical and Wangshan Wangshui have reached an exclusive licensing agreement for deuterium remidevir hydrobromide for new indications such as RSV infection December 4, 2025
- SAL0140 tablets approved for clinical trials for the treatment of chronic kidney disease December 4, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
